Literature DB >> 32736296

The effects of isoliquiritigenin on endometriosis in vivo and in vitro study.

Yi-Wen Hsu1, Hsin-Yuan Chen1, Yi-Fen Chiang1, Li-Chun Chang1, Po-Han Lin1, Shih-Min Hsia2.   

Abstract

BACKGROUND: Endometriosis is a common gynaecological disease characterized by growth of uterine endometrial tissue, outside the uterine cavity, on the ovaries, oviduct and pelvic peritoneum. Isoliquiritigenin (ISL) is a natural flavonoid isolated from the root of licorice (Glycyrrhiza uralensis) and shallot (Allium cepa). ISL has previously shown antioxidant, anti-inflammatory, anti-proliferation and anti-tumor activities.
PURPOSE: This study aimed to investigate the effects of ISL on endometriosis in vivo and in vitro.
METHODS: End1/E6E7 endometriosis cells were treated with ISL and β-estradiol. The MTT assay was used to detect cell viability. Cell migration was evaluated by the wound-healing assay. The expression of epithelial-to-mesenchymal transition (EMT)-related proteins were detected by western blot. Female Balb/c mice, surgically induced to have endometriosis by transplanting uterine tissue into the abdominal cavity, were treated with ISL or vehicle for 4 weeks. Lesion growth was subsequently analyzed by high-resolution ultrasound imaging. Serum and lesion inflammatory cytokines were measured by ELISA. EMT-related proteins and apoptosis-related proteins of endometriotic lesions were detected by western blot.
RESULTS: It was observed that ISL treatment inhibited the viability and migration of End1/E6E7. ISL treatment increased the expression of E-cadherin, and decreased the expression of N-cadherin, Slug and Snail. In the animal model, ISL treatment reduced the volume and weight of endometriotic lesions, decreased serum and lesion inflammatory cytokines, inhibited EMT, and induced apoptosis of the lesions.
CONCLUSION: ISL inhibited the viability, migration and EMT-related proteins of End1/E6E7 cells, reduced the volume and weight of endometriotic lesions, inhibited inflammatory cytokines and EMT, and induced apoptosis of the lesions to improve endometriosis.
Copyright © 2020 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Endometriosis; Epithelial-mesenchymal transition; Inflammatory; Isoliquiritigenin

Year:  2020        PMID: 32736296     DOI: 10.1016/j.phymed.2020.153214

Source DB:  PubMed          Journal:  Phytomedicine        ISSN: 0944-7113            Impact factor:   5.340


  6 in total

1.  Isoliquiritigenin attenuates pathological cardiac hypertrophy via regulating AMPKα in vivo and in vitro.

Authors:  Meiling Gao; Qiang Cai; Haichao Si; Si Shi; Huixia Wei; Miaomiao Lv; Xiaofan Wang; Tieli Dong
Journal:  J Mol Histol       Date:  2022-07-14       Impact factor: 3.156

2.  A Mouse Model of Endometriosis with Nanoparticle Labeling for In Vivo Photoacoustic Imaging.

Authors:  Ryan M Marquardt; Md Nafiujjaman; Tae Hoon Kim; Seock-Jin Chung; Kay Hadrick; Taeho Kim; Jae-Wook Jeong
Journal:  Reprod Sci       Date:  2022-05-31       Impact factor: 2.924

Review 3.  Natural Products for the Prevention and Treatment of Oral Mucositis-A Review.

Authors:  Ana Sofia Ferreira; Catarina Macedo; Ana Margarida Silva; Cristina Delerue-Matos; Paulo Costa; Francisca Rodrigues
Journal:  Int J Mol Sci       Date:  2022-04-15       Impact factor: 6.208

4.  The Potential Effect of Fucoidan on Inhibiting Epithelial-to-Mesenchymal Transition, Proliferation, and Increase in Apoptosis for Endometriosis Treatment: In Vivo and In Vitro Study.

Authors:  Li-Chun Chang; Yi-Fen Chiang; Hsin-Yuan Chen; Yun-Ju Huang; An-Chieh Liu; Shih-Min Hsia
Journal:  Biomedicines       Date:  2020-11-22

Review 5.  Pathogenesis of Endometriosis: New Insights into Prospective Therapies.

Authors:  Radhika Kapoor; Christina Anna Stratopoulou; Marie-Madeleine Dolmans
Journal:  Int J Mol Sci       Date:  2021-10-28       Impact factor: 5.923

Review 6.  An Update on the Multifaceted Role of NF-kappaB in Endometriosis.

Authors:  Yuanmeng Liu; Jianzhang Wang; Xinmei Zhang
Journal:  Int J Biol Sci       Date:  2022-07-04       Impact factor: 10.750

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.